+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression



A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression



Journal of Psychopharmacology 12(3): 273-278



A multicentre, randomized, double-blind study was conducted to compare the safety and antidepressant efficacy of venlafaxine and clomipramine in 102 outpatients with major depression. The patients received either venlafaxine or clomipramine at a dose titrated from 50 mg to a maximum of 150 mg/day during the first 2 weeks of treatment. Treatment was continued for up to 43 days. Montgomery Asberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HAM-D) scores decreased significantly (p < or = 0.05) from baseline in each treatment group but were not significantly different between groups. Response rates on the MADRS and HAM-D were 62% and 59%, respectively, with venlafaxine and 54% and 43%, respectively, with clomipramine. Treatment-emergent study events were the primary reason for withdrawal in only 13% of venlafaxine-treated patients and 20% of clomipramine-treated patients. On questionnaires, the incidence of anticholinergic-type events was 60% with venlafaxine and 68% with clomipramine. However, significantly (p = 0.043) more patients in the clomipramine group reported multiple anticholinergic events than in the venlafaxine group. In the clomipramine group, mean ventricular heart rate increased significantly (p = 0.003) and mean systolic blood pressure decreased significantly (p = 0.028) from baseline, but no clinically significant electrocardiographic changes were observed. These results confirm the efficacy and safety of venlafaxine in the treatment of outpatients suffering from major depression.

(PDF emailed within 1 workday: $29.90)

Accession: 045102728

Download citation: RISBibTeXText

PMID: 10958254


Related references

Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. Journal of Clinical Psychiatry 61(2): 95-100, 2000

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry 59(7): 352-357, 1998

Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. Journal of Affective Disorders 76(1-3): 191-200, 2003

Multicenter double-blind randomized parallel-group clinical trial of effectiveness of the combination clomipramine plus lithium carbonate versus clomipramine plus placebo in the treatment of unipolar major depression. European Neuropsychopharmacology 10(Supplement 3): S249, 2000

A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. International Journal of Clinical Practice 51(4): 209-213, 1997

Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. Journal of Psychopharmacology 14(1): 61-66, 2000

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress In Neuro-Psychopharmacology & Biological Psychiatry. 20(1): 57-71, 1996

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. International Clinical Psychopharmacology 9(3): 139-143, 1994

Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. American Journal of Psychiatry 159(11): 1869-1875, 2002

Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry 55(7): 301-305, 1994

An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. American Journal of Psychiatry 160(7): 1277-1285, 2003

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in patients with major depression and melancholia. Journal of Psychiatric Research 30(6): 441-451, 1996

A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. International Clinical Psychopharmacology 15(5): 263-271, 2000

A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. American Journal of Geriatric Psychiatry 14(4): 361-370, 2006

Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. Journal of Clinical Psychiatry 69(4): 571-577, 2008